Multiple Myeloma

Data suggests Quadramet provides pain relief for certain cancer patients

Published in Blood Weekly, January 8th, 2004

Cytogen Corporation (CYTO) announced the presentation of data from two studies using Quadramet (Samarium Sm-153 lexidronam injection) at the 45th Annual Meeting of the American Society of Hematology (ASH).

Quadramet is the company's lead therapeutic product approved for the treatment of bone pain associated with cancer.

Data from a pilot study presented by Francesco Iuliano, MD, Hematology-Oncology Dept., Azienda Ospedaliera Pugliese Ciaccio, Catanzaro, Italy, and coauthored by Elisabetta Abruzzese, MD, PhD, Division of Hematology, S. Eugenio Hospital at University of Tor Vergata, Rome, Italy, showed that Quadramet, in combination with zoledronic...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2004-01-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry